Compare SKYX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | MDWD |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | United States | Israel |
| Employees | 73 | N/A |
| Industry | Building Products | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.8M | 162.2M |
| IPO Year | 2014 | 2013 |
| Metric | SKYX | MDWD |
|---|---|---|
| Price | $1.01 | $12.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $4.00 | ★ $30.67 |
| AVG Volume (30 Days) | ★ 549.2K | 63.0K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $16.10 | $39.60 |
| Revenue Next Year | $27.95 | $34.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.95 | $11.90 |
| 52 Week High | $3.29 | $20.03 |
| Indicator | SKYX | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 31.96 | 34.88 |
| Support Level | $0.98 | N/A |
| Resistance Level | $1.12 | $14.06 |
| Average True Range (ATR) | 0.05 | 0.42 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 16.09 | 14.52 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.